ATLANTA (PRWEB)
November 12, 2019

AI for preventable harm analytics leader Jvion today announced that Jvion was included in the latest KLAS report “Healthcare AI 2019 – Actualizing the Potential of AI”, which provides a “tip of the spear” analysis of the healthcare AI market. As the market leader and the only healthcare-focused AI company with enough clients to complete a full KLAS analysis, Jvion was featured as having “by far the largest client base in the healthcare AI market,” and as having “the largest offering of prebuilt healthcare content for machine learning models/vectors.” Jvion is also proud to share that 95% of its clients said they would buy from Jvion again and that Jvion was part of their long-term plans.

Jvion was identified as the only validated vendor in this space, citing that KLAS was able to interview a larger number of customers, making Jvion the only fully rated vendor meeting the required customer threshold for this report. All other vendors, which included large, global companies, had fewer validated use cases. KLAS validated Jvion for diverse types of clinical and operational use cases, citing that “this puts Jvion at the top of measured vendors in terms of number of validated use cases and number of unique use cases,” and adds that “Jvion’s solution takes results from predictive models and provides prescriptive guidance for how to use that data.” KLAS also reported that 95% of Jvion’s clients responded yes to “would you buy again” and “part of long term plans.”

As summarized in FierceHealthcare, healthcare providers profiled in the report cited early success with clinical outcomes such as reducing readmissions and detecting sepsis risk. One healthcare senior vice president and CMIO said using AI software from Jvion has helped the organization reduce readmissions through the identification of patients more likely to be admitted with an accuracy of 80% to 90%.

As part of the report, Jvion customers also shared:

• ”Jvion is very focused on the clinical processes of care and making sure that we use AI to inform the clinicians and to augment what they do. That is Jvion’s main goal, and that results in better financial outcomes.”
• “Jvion is a fantastic partner. I thoroughly enjoy working with them. They are willing to partner and show some of their secret sauce. They want to be with us on every step of the way. They want to be a guide. That is one of the strongest components of our relationship. The vendor is fantastic at helping us be successful.”

Jvion has also been proactively addressing feedback on improvements, highlighted in the reported customer interviews, iteratively introducing them over the past 6 months, including

• Proactively hiring additional clinical adoption consultants to address the change management and adoption needs specific to AI and healthcare;
• Refining the ROI reporting through dedicated teams focused on the communication process at three levels- technical, clinical, and executive-level reporting
• Providing more frequent Jvion user group meetings and training opportunities to leverage AI community learning and best practices.

“As a trailblazer in this complex market, Jvion knows firsthand that being the innovator enables the way to better outcomes, care and support for patients, but it also comes with discovering and tackling things for the very first time,” shared Niki Ozment Buchanan, Jvion’s newly appointed SVP of Customer Success. “Jvion has always looked at these challenges as a privilege and opportunity to learn, adapt and optimize our solutions, approach and support for our customers. This is why I am excited to take customer success to the next level as we continue to partner with providers.”

With over 50% of provider organizations saying they are deployed, implementing or looking to buy a Purpose-built AI vendor solution, based on CHIME’s 2019 HealthCare’s Most Wired Report on AI Adoption based on responses from 483 provider organizations, the Healthcare AI 2019 report from KLAS provides much-needed analysis and guidance to equip providers to adopt AI for patient and provider success.

“The most exciting insight from our research is that artificial intelligence has truly begun to make a difference in healthcare. It’s not all just smoke,” Ryan Pretnik, director of research and strategy at KLAS and co-author of the study, shared with FierceHealthcare. “Artificial intelligence is driving outcomes, saving patient lives, and driving operational and financial efficiencies for providers and payers.”

“This is a great testament to the potential of Jvion’s AI approach for preventing harm while saving costs. It comes from many years of working hand in hand with some very forward-thinking healthcare organizations, helping us gain the experience needed to solve very complex healthcare problems,” adds Shantanu Nigan, co-founder and CEO of Jvion. ”Our client base today represents many of the best hospitals in North America and their continued support of Jvion as we collectively learn how to leverage the power of AI in healthcare is inspiring, driving us to continually strengthen our AI solution.”

The KLAS report was based on interviews with IT leaders at 57 organizations – CIOs, CMIOs, data scientists and more – that are using AI across a variety of different cases, from clinical decision support to patient engagement to revenue cycle management. As part of this process, participants were asked to discuss some tangible gains realized through the technology.

About Jvion

Jvion delivers healthcare’s only AI-driven prescriptive analytics for preventable harm solution. By using Eigen-based technology, the machine does what simple predictive analytics or machine learning models cannot. It goes beyond high-risk patient populations to identify those on a trajectory to becoming high risk. Jvion determines the interventions that will more effectively reduce risk and enable clinical action. And it accelerates time to value by leveraging established patient-level intelligence to drive engagement across hospitals, populations, and patients. For more information, visit http://www.jvion.com.

###

Share article on social media or email:

CHICAGO (PRWEB)
November 12, 2019

Ruth A. Bahe-Jachna, a shareholder in the Chicago office of global law firm Greenberg Traurig, LLP, will receive the Illinois Lawyers’ Assistance Program’s (LAP) Executive Director’s Award at the Program’s Annual Dinner, Nov. 14.

The LAP is a not-for-profit organization that helps Illinois lawyers, judges, law students, and their families concerned about alcohol abuse, drug dependency, or stress related issues like anxiety, burnout, depression, and many others. The Executive Director’s Award is presented to an individual who significantly contributed to the goals and mission of LAP and supported the executive director in her role, according to the organization.

Bahe-Jachna has more than 30 years of experience working on and managing large-scale litigation matters. She regularly defends clients in class actions and product liability and consumer fraud litigation in state and federal courts, as well as in employment-related class actions and FLSA collective actions. She regularly counsels clients on a wide variety of product safety and risk management matters, including providing guidance on U.S. Consumer Product Safety Commission (CPSC) reporting requirements, recall issues and appropriate recall processes, and drafting release and waiver forms, warning labels, and warranties. An active member of the American Bar Association, Bahe-Jachna recently served as co-chair of the ABA Litigation Section’s Attorney Mental Health & Wellness Task Force, and continues to work with that Task Force in an advisory capacity.

About Greenberg Traurig: Greenberg Traurig, LLP (GT) has approximately 2100 attorneys in 41 locations in the United States, Latin America, Europe, Asia, and the Middle East. GT has been recognized for its philanthropic giving, diversity, and innovation, and is consistently among the largest firms in the U.S. on the Law360 400 and among the Top 20 on the Am Law Global 100. Web: http://www.gtlaw.com Twitter: @GT_Law.

Share article on social media or email:

NEW ORLEANS (PRWEB)
November 12, 2019

Four of the 34 statewide class actions pending before Judge Dan Polster’s Multi-District Litigation have been amended with evidence pleading the causal connection between in-utero prescription opioid use and birth defects in exposed fetuses, said Lead Counsel Scott Bickford.

“For the first time, the dirty secret regarding prescription opioids prescribed to women of child-bearing age is revealed,” said Legal Strategist Stuart Smith. “Our research shows that though the federal agencies documented the link between in-utero exposure to prescription opioids and birth defects, a timely black box warning on opioid prescriptions given to women by their doctors and gynecologists could have and should have been made before 2014, when the first warning in opioid labeling was made.”

These cases now present a legal model for replication in all cases, Mr. Bickford said. The suits were filed seeking to protect the rights of babies born opioid-dependent and their guardians because these children will face life-time medical needs related to educational, physical, and developmental disabilities.

“The responsible parties who should have warned prescribers of opioids to women of childbearing age, never undertook a Risk Evaluation and Mitigation Strategy (REMS) similar to other proven teratogens,” said Mr. Bickford. “These cases are an important public warning to women and their babies because they were left unprotected during decades of widespread distribution, marketing and medical use of these drugs.”

The four amended cases in West Virginia, California, Tennessee and Ohio document the birth defects and complications children born before 2014 to mothers using prescription opioids are now facing, along with the scientific links alleging the mechanism of action by which this class of prescription opioid drugs caused these debilitating injuries.

The amended briefs include research conducted by Toxicological Pathologist Dr. Vyvyan Howard of Ulster University and Neo-Natal Abstinence Syndrome (NAS) Expert Dr. Kanwaljeet Anand of Stanford University. The teratogenic effects of opioids on a developing fetus range from physical deformities such as heart, brain and gastroenterological defects, including mal-formed heads, cleft palates or lack of complete bowel systems, as well as neurological, motor and cognitive defects such as inability to walk, talk or complete basic skills.

“The hard work of these independent researchers has uncovered the sorry details of this public health crisis, but we remain concerned that these facts will get lost in the fights over bankruptcies and counter lawsuits,” said Mr. Bickford. “This information must get out to every doctor and pharmacy, and a REMS program instituted to protect every woman of child-bearing age who might be prescribed these risky drugs.

“Hundreds of thousands of Opioid Dependent Children have been born in the last 20 years. These children face educational and developmental hurdles, and many may face future addiction since they were born addicted. We continue to push aggressively in the federal court system and before Judge Polster presiding over the Multi-District Litigation for a specific NAS track because of the severe and enduring impact this epidemic has and will have on our nation’s children.

Table 1 shows the association between maternal opioid analgesic treatment and specific major birth defects in National Birth Defects Prevention Study of 17449 cases and 6701 controls. Significance is starred * in the usual way. Odds ratios were adjusted for maternal age, race/ethnicity, education, pre-pregnancy obesity, smoking.

“The lawsuits seek creation of a medical monitoring trust fund for these children funded by the prescription drug defendants directly, rather than relying on local governments with competing priorities,” Mr. Bickford said, illustrating the gravity of the situation by estimating that an opioid-dependent child is being born every 15 minutes in the United States.

Statistics compiled by the Centers for Disease Control estimate that first-year Medicaid costs for opioid-exposed infants average approximately $238,000 and the additional cost burden on hospital Neo-natal Intensive Care Units has increased five-fold in less than a decade.

“These estimates do not cover costs borne by family caregivers or foster-care institutions responsible for the infants once released from the hospital. The guardians and parents who take these infants home frequently believe that once the child is weaned from their opioid-dependency, there will be no long-term impact on the child. Data shows that is unfortunately almost never the case,” said Mr. Bickford.

The 34 states represented in the NAS legal filings are:

Alabama, Arkansas, Arizona, California, Colorado, Delaware, Georgia, Illinois, Indiana, Kentucky, Louisiana, Maryland, Massachusetts, Michigan, Minnesota, Missouri, Montana, Nevada, New Jersey, New Mexico, New York, North Carolina, North Dakota, Ohio, Oklahoma, Oregon, Pennsylvania, South Carolina, Tennessee, Utah, Virginia, Washington, West Virginia, Wisconsin.

Share article on social media or email: